Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy O'Brien

Showing results (1-10 of 338) with videos related to

Pageof 34
Sort By:
Diabetes|April 25, 2013
Gene therapy for type 1 diabetes moves a step closer to realityTimothy O'Brien
Bio-Medical Materials and Engineering|December 10, 2008
Genetic engineering of the blood vessel wall to improve nitric oxide bioavailabilityTimothy O'Brien
The Journal of Urology|April 23, 2013
Is fluorescent cystoscopy of cost/benefit/therapeutic value for carcinoma in situ of the bladder? No (a difficult task)Timothy O'Brien
The Lancet. Oncology|February 3, 2022
Immune checkpoint inhibitors and timing of administrationTimothy O'Brien, Leonie Dolan
Expert Opinion on Biological Therapy|January 12, 2011
Stem cell therapy for cardiac diseaseAidan Flynn, Timothy O'Brien
Biochemical and Biophysical Research Communications|April 5, 2007
Beta cell cytoprotection using lentiviral vector-based iNOS-specific shRNA deliveryCillian McCabe, Timothy O'Brien
Idrugs : the Investigational Drugs Journal|April 2, 2008
Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery diseaseAidan Flynn, Timothy O'Brien
Stem Cell Research & Therapy|August 1, 2012
Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemiaAaron Liew, Timothy O'Brien
International Journal of Hematology|December 23, 2003
Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndromeAnat Galor, Timothy O'Brien
Molecular Biotechnology|October 5, 2007
The rational design of beta cell cytoprotective gene transfer strategies: targeting deleterious iNOS expressionCillian McCabe, Timothy O'Brien
Pageof 34

Showing results (1-10 of 338) with videos related to

Sort By:
Pageof 34
Diabetes|April 25, 2013
Gene therapy for type 1 diabetes moves a step closer to realityTimothy O'Brien
Bio-Medical Materials and Engineering|December 10, 2008
Genetic engineering of the blood vessel wall to improve nitric oxide bioavailabilityTimothy O'Brien
The Journal of Urology|April 23, 2013
Is fluorescent cystoscopy of cost/benefit/therapeutic value for carcinoma in situ of the bladder? No (a difficult task)Timothy O'Brien
The Lancet. Oncology|February 3, 2022
Immune checkpoint inhibitors and timing of administrationTimothy O'Brien, Leonie Dolan
Expert Opinion on Biological Therapy|January 12, 2011
Stem cell therapy for cardiac diseaseAidan Flynn, Timothy O'Brien
Biochemical and Biophysical Research Communications|April 5, 2007
Beta cell cytoprotection using lentiviral vector-based iNOS-specific shRNA deliveryCillian McCabe, Timothy O'Brien
Idrugs : the Investigational Drugs Journal|April 2, 2008
Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery diseaseAidan Flynn, Timothy O'Brien
Stem Cell Research & Therapy|August 1, 2012
Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemiaAaron Liew, Timothy O'Brien
International Journal of Hematology|December 23, 2003
Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndromeAnat Galor, Timothy O'Brien
Molecular Biotechnology|October 5, 2007
The rational design of beta cell cytoprotective gene transfer strategies: targeting deleterious iNOS expressionCillian McCabe, Timothy O'Brien
Pageof 34